Long Noncoding RNAs: From Clinical Genetics to Therapeutic Targets?

详细信息    查看全文

• 作者：Reinier A. Boon ; PhD^a ; ^b ; Nicolas Jaé ; PhD^a ; Lesca Holdt ; MD ; PhD^b ; ^c ; Stefanie Dimmeler ; PhD^a ; ^b ; ^{dimmeler@em.uni-frankfurt.de" class="auth_mail" title="E-mail the corresponding author}
• 关键词：cardiac ; long noncoding RNA ; microRNA ; vascular
• 刊名：Journal of the American College of Cardiology
• 出版年：2016
• 出版时间：15 March 2016
• 年：2016
• 卷：67
• 期：10
• 页码：1214-1226
• 全文大小：1688 K

文摘

Recent studies suggest that the majority of the human genome is transcribed, but only about 2% accounts for protein-coding exons. Long noncoding RNAs (lncRNAs) constitute a heterogenic class of RNAs that includes, for example, intergenic lncRNAs, antisense transcripts, and enhancer RNAs. Moreover, alternative splicing can lead to the formation of circular RNAs. In support of putative functions, GWAS for cardiovascular diseases have shown predictive single-nucleotide polymorphisms in lncRNAs, such as the 9p21 susceptibility locus that encodes the lncRNA antisense noncoding RNA in the INK4 locus (ANRIL). Many lncRNAs are regulated during disease. For example, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and myocardial infarction-associated transcript (MIAT) were shown to affect endothelial cell functions and diabetic retinopathy, whereas lincRNA-p21 controls neointima formation. In the heart, several lncRNAs were shown to act as microRNA sponges and to control ischemia-reperfusion injury or act as epigenetic regulators. In this review, the authors summarize the current understanding of lncRNA functions and their role as biomarkers in cardiovascular diseases.